A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Public ClinicalTrials.gov record NCT01937715. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multi-Center, Randomized Phase 1b/2 Study Of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus FOLFIRI. The randomized, two-arm Phase 2 portion will compare the efficacy and safety of PF-05212384 plus FOLFIRI to that of bevacizumab plus FOLFIRI. The study population will consist of patients with mCRC previously treated with an oxaliplatin-based regimen in the first line setting or who have progressed within 6 months of the end of an adjuvant oxaliplatin-based regimen.
Study identification
- NCT ID
- NCT01937715
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Interventions
- PF-05212384 Drug
- FOLFIRI regimen Drug
- Bevacizumab Biological
- FOLFIRI Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2014
- Primary completion
- Jul 31, 2015
- Completion
- Jul 31, 2015
- Last update posted
- Aug 17, 2016
2014 – 2015
United States locations
- U.S. sites
- 35
- U.S. states
- 5
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare | Fullerton | California | 92835 | — |
| UCLA Hematology Oncology | Irvine | California | 92604 | — |
| Drug Management Only: UCLA West Medical Pharmacy, Attn Steven L. Wong, Pharm .D. | Los Angeles | California | 90095-7349 | — |
| Drug Management Only: UCLA West Medical Pharmacy | Los Angeles | California | 90095-7349 | — |
| UCLA West Medical Pharmacy, Att: Steven L. Wong, Pharm D. | Los Angeles | California | 90095-7349 | — |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | — |
| Ronald Regan UCLA Medical Center, Drug Information Center | Los Angeles | California | 90095 | — |
| TRIO-US Central Administration, Regulatory Management Only | Los Angeles | California | 90095 | — |
| TRIO-US Central Administration | Los Angeles | California | 90095 | — |
| TRIO_US | Los Angeles | California | 90095 | — |
| UCLA Hematology Oncology Administrative Address | Los Angeles | California | 90095 | — |
| Westwood Bowyer Clinic, Peter Morton Medical Building | Los Angeles | California | 90095 | — |
| West Valley Hematology/Oncology Med Group | Northridge | California | 91328 | — |
| UCLA/Pasadena Healthcare | Pasadena | California | 91105 | — |
| Central Coast Medical Oncology Corporation | Santa Maria | California | 93454 | — |
| UCLA Hematology Oncology | Santa Monica | California | 90404 | — |
| UCLA Santa Monica Medical Center & Orthopaedic Hospital | Santa Monica | California | 90404 | — |
| UCLA/Santa Clarita Valley Cancer Center | Valencia | California | 91355 | — |
| UCLA Cancer Center | Westlake Village | California | 91361 | — |
| Comprehensive Cancer Centers of Nevada Research Department | Henderson | Nevada | 89014 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89052 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89074 | — |
| Comprehensive Cancer Centers of NV | Las Vegas | Nevada | 89128 | — |
| COmprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89148 | — |
| Comprehensive Cancer Centers for Nevada | Las Vegas | Nevada | 89169 | — |
| Metrohealth Medical Center | Cleveland | Ohio | 44109 | — |
| Medical Group of the Carolinas - Hematology Spartanburg | Spartanburg | South Carolina | 29303 | — |
| Spartanburg Regional Medical Center | Spartanburg | South Carolina | 29303 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| Kadlec Medical Center | Richland | Washington | 99352 | — |
| Outpatient Imaging Center | Richland | Washington | 99352 | — |
| Investigational Drug Services | Seattle | Washington | 98101 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Medical Oncology Associates, PS | Spokane | Washington | 99208 | — |
| Spokane Valley Cancer Center | Spokane Valley | Washington | 99216 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01937715, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2016 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01937715 live on ClinicalTrials.gov.